Human Papillomavirus Vaccine (HPV) Market
Global Human Papillomavirus Vaccine Market Size, Share, and Trends Analysis Report By Type (Bivalent, Quadrivalent, and Nonavalent) and By Indication (Cervical Cancer, Anal Cancer, Penile Cancer, Vaginal Cancer, Oropharyngeal Cancer, Genital Warts and Others) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global human papillomavirus vaccine market is anticipated to grow at a significant CAGR of 7.1% during the forecast period 2022-2028. The rising prevalence of HPV-related malignancies of the anus, vulva, vagina, penile, and oropharynx, along with the growing demand for prevention of these infections, are the driving factors supporting the growth of the forecast period. Additionally, during the forecast period, government initiatives for HPV vaccination programs are expected to enhance the market growth. For instance, in June 2020, around 55% of WHO member states had implemented HPV vaccination. Furthermore, rising healthcare infrastructure and spending in emerging countries are likely to open up human papillomavirus vaccine market prospects. However, government rules governing the manufacture of new vaccines, on the other hand, are expected to stifle market expansion.
Impact of Covid-19 on Global Human Papillomavirus Vaccine Market
The COVID-19 pandemic had a significant impact on the global human papillomavirus vaccine market, disrupting many critical health services, including routine immunization procedures. Transportation disruptions, health personnel being unavailable due to safety and health concerns, and also due to a shortage of personal protective equipment, are all contributing causes. People have been hesitant to leave their homes to get immunized due to restrictions on movement or fear of being exposed to people who have COVID-19. All these factors have contributed to the decline in the growth of the market.
Segmental Outlook
The global human papillomavirus vaccine market is segmented based on type and indication. Based on the type, the market is sub-segmented into bivalent, quadrivalent, and nonavalent. Based on indication, the market is sub-segmented into cervical cancer, anal cancer, penile cancer, vaginal cancer, oropharyngeal cancer, genital warts, and others.
Global Human Papillomavirus Vaccine Market Share by Indication, 2021 (%)
The Cervical Cancer Segment is Anticipated to Hold a Prominent Share in the Global Human Papillomavirus Vaccine Market
The cervical cancer segment is anticipated to hold a significant share in the market due to its increased cases of cervical cancer in lower-income countries. The human papillomavirus is responsible for nearly all cases of cervical cancer. In addition, extremely sensitive and specific molecular assays are now provided in cervical cancer screening to identify high-risk HPV types from DNA. Furthermore, according to the US National Institute of Health, cervical cancer, which was previously one of the most prevalent malignancies among women in the US, is now the 14th most common cancer in women in the US. However, in developing nations, where more than 80% of cervical cancer cases occur, rates remain high which is also impacting the growth of the segment.
Regional Outlooks
The global human papillomavirus vaccine market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East & Africa, and Latin America).
Global Human Papillomavirus Vaccine Market Growth, by Region 2022-2028
The North America Region is Estimated to Hold the Major Share in the Global Human Papillomavirus Vaccine Market
The North American region is expected to hold a significant share in the global human papillomavirus vaccine market due to the rising cases of various different types of cancers in the region. Additionally, due to the effective healthcare infrastructure, the US is likely to be a significant market for HPV vaccines. According to the American Sexual Health Association, around 14 million new instances of sexually transmitted HPV are diagnosed each year in the US, with at least 79 million people currently infected. The rising number of cases is predicted to drive the market's growth in the region. Additionally, higher Gardasil sales and value, and widespread uptake of human papillomavirus vaccines, will support the region's prosperity.
Market Players Outlook
GlaxoSmithKline PLC, Sanofi SA, Bharat Biotech Ltd, Serum Institute of India Pvt. Ltd. among others, are some of the leading participants in the global human papillomavirus vaccine market industry. To increase market share around the globe, these companies are using a variety of techniques, including mergers and acquisitions, product launches, geographic expansion and collaboration, and partnership.
For instance, in July 2020, U.S. Food and Drug Administration (FDA) approved an expanded indication for Merck & Co. Inc., Gardasil 9-a human papillomavirus (HPV) nine-valent vaccine for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global human papillomavirus vaccine market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Human Papillomavirus Vaccine Market
- Recovery Scenario of Global Human Papillomavirus Vaccine Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Human Papillomavirus Vaccine Market by Type
4.1.1. Bivalent
4.1.2. Quadrivalent
4.1.3. Nonavalent
4.2. Global Human Papillomavirus Vaccine Market by Indication
4.2.1. Cervical Cancer
4.2.2. Anal Cancer
4.2.3. Penile Cancer
4.2.4. Vaginal Cancer
4.2.5. Oropharyngeal Cancer
4.2.6. Genital Warts
4.2.7. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. A-S Medical Solutions LLC
6.2. AstraZeneca PLC
6.3. Bavarian Nordic A/S
6.4. Bharat Biotech Ltd.
6.5. GlaxoSmithKline PLC
6.6. Innovax Pharmaceutical LLP
6.7. Inovio Pharmaceuticals Inc.
6.8. Johnson & Johnson Services Ltd.
6.9. Merck & Co. Inc.
6.10. Sanofi SA
6.11. Serum Institute of India Pvt. Ltd.
1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL BIVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL NONAVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
6. GLOBAL CERVICAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL ANAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL PENILE CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL VAGINAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL OROPHARYNGEAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL GENITAL WARTS HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL OTHERS HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
14. NORTH AMERICAN HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. NORTH AMERICAN HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
16. NORTH AMERICAN HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
17. EUROPEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. EUROPEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
19. EUROPEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
23. REST OF THE WORLD HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
24. REST OF THE WORLD HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
25. REST OF THE WORLD HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, 2022-2028 (%)
4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL BIVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL NONAVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY INDICATION, 2021 VS 2028 (%)
9. GLOBAL CERVICAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL ANAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL PENILE CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL VAGINAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL OROPHARYNGEAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL GENITAL WARTS HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL OTHERS HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. US HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
18. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
19. UK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
20. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
21. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
22. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
23. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
25. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
26. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
27. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
